Intellectus Partners’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Intellectus Partners’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-13,000	Closed	-$35K	–	552
2018 Q3	$35K	Hold	13,000	–	–	0.01%	379
2018 Q2	$25K	Hold	13,000	–	–	0.01%	406
2018 Q1	$27K	Hold	13,000	–	–	0.01%	401
2017 Q4	$26K	Hold	13,000	–	–	0.01%	406
2017 Q3	$17K	Hold	13,000	–	–	0.01%	565
2017 Q2	$20K	Hold	13,000	–	–	0.01%	514
2017 Q1	$42K	Buy	+13,000	New	+$32K	0.02%	363

Other funds holding INFI

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return

Intellectus Partners's INFI Position: Q4 2018 in Review

Intellectus Partners sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q4 2018, closing a stake of 13,000 shares — an estimated $35K sold.

Intellectus Partners first reported a position in INFI in Q1 2017 and held it in 7 quarters. The position peaked at $42K in Q1 2017. 64 funds tracked by Wall St. Rank hold INFI as of Q4 2018.

Intellectus Partners reported no remaining Infinity Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Intellectus Partners sold 13,000 Infinity Pharmaceuticals, Inc. shares in Q4 2018, an estimated $35K.
Intellectus Partners first reported a position in Infinity Pharmaceuticals, Inc. in Q1 2017 and held it in 7 quarters.
Intellectus Partners's Infinity Pharmaceuticals, Inc. position peaked at $42K in Q1 2017.
64 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q4 2018.

Based on Intellectus Partners's 13F filing for Q4 2018, filed 14 Feb 2019.